Eric Nuermberger, MD

Eric Nuermberger, M.D. is Associate Professor of Medicine and International Health at Johns Hopkins University. He has been involved in the development of new anti-tubercular agents since 2001. His research using in vitro and animal models of tuberculosis to optimize dosing of new and existing drugs and design optimal drug combinations has informed the clinical development of moxifloxacin, rifapentine, pretomanid, bedaquiline and sutezolid and the pre-clinical development of numerous other compounds. It is funded by the National Institutes of Health, the U.S. Food and Drug Administration, the Bill and Melinda Gates Foundation, the Global Alliance for TB Drug Development, and various pharmaceutical companies. Dr. Nuermberger is a member of the AIDS Clinical Trial Group’s TB Transformative Science Group and the Core Science Group of the TB Trials Consortium.  He is also Co-Chair of the Preclinical and Clinical Sciences Work Group of the Critical Path to TB Drug Regimens (CPTR) initiative. Dr. Nuermberger also serves as an Associate Editor of the Antimicrobial Agents and Chemotherapy and the International Journal of TB and Lung Disease.

  • Investigator, TB Transformative Science Group (Dec 2016)
  • Investigator, Protocol team A5279
  • Investigator, Protocol team A5356

Categories

Leadership Committees
CRS
Roles

Clinical Trials

A5300B/I2003B/PHOENIX, Protecting Households On Exposure to...

This study will compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing...

Read More

A5225: Phase I/II Dose-Finding Study of High-Dose...

A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...

Read More

P1077FF: Formula Feeding Version of the PROMISE Study...

1077FF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

Read More

P1077BF: Breastfeeding Version of the PROMISE Study...

1077BF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

Read More

P1073: Study of Immune Reconstitution Inflammatory Syndrome...

P1073 is a case controlled prospective, clinical, observational and pathogenesis study of HIV-infected infants and children...

Read More